Bohui Innovation(300318)2025-04-28 08:20Financial Performance - The company's revenue for Q1 2025 was ¥201,657,154.39, a decrease of 23.05% compared to ¥262,051,377.78 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥4,054,437.18, representing a decline of 120.41% from a profit of ¥19,863,584.33 in the previous year[5] - Basic and diluted earnings per share were both -¥0.0050, down 120.58% from ¥0.0243 in the same quarter last year[5] - Total operating revenue decreased to ¥201,657,154.39 from ¥262,051,377.78, representing a decline of approximately 23% year-over-year[30] - Net profit for the period was -¥57,221.71, compared to a net profit of ¥42,022,580.71 in the previous period, indicating a significant decline[31] - The company reported a loss attributable to the parent company of -¥4,054,437.18, down from a profit of ¥19,863,584.33 in the prior year[31] Cash Flow - The net cash flow from operating activities was negative at ¥29,492,711.31, a decrease of 192.42% compared to ¥31,910,106.63 in Q1 2024[5] - The cash flow from operating activities showed a significant decline, primarily due to decreased sales revenue and collections[15] - Cash inflow from operating activities totaled 277,422,518.85 in the previous period[35] - Net cash outflow from operating activities was -31,910,106.63 in the previous period[35] - The company reported a cash inflow of 6,695,622.97 in the previous period[35] - The net cash flow from investing activities was -72,546,642.65 in the previous period, indicating improved investment efficiency[36] Assets and Liabilities - Total assets increased by 6.21% to ¥4,381,583,602.25 from ¥4,125,558,100.42 at the end of the previous year[5] - Total liabilities rose to ¥2,032,224,210.96 from ¥1,776,429,561.09, an increase of about 14.4%[26] - The total equity attributable to shareholders decreased slightly to ¥1,374,920,641.38 from ¥1,378,686,990.40, a decline of about 0.3%[27] - Long-term borrowings rose by 71.03% to ¥666,819,504.06, primarily due to increased loans from subsidiaries[10] - The company’s long-term borrowings increased to ¥666,819,504.06 from ¥389,879,354.06, indicating a rise of approximately 71%[26] Financing Activities - The company reported a significant increase in cash received from financing activities, totaling ¥286,000,000.00, up 209.19% from ¥92,500,000.00 in the previous year[15] - Cash inflow from financing activities increased significantly to 281,668,207.13 in the previous period[36] - Net cash flow from financing activities was 26,943,879.85 in the previous period, indicating a strong financing position[36] - The company received 189,168,207.13 in the previous period, reflecting increased leverage[36] Operational Highlights - The company received government subsidies amounting to ¥820,053.86, which are closely related to its normal business operations[7] - The company’s subsidiary, Guangdong Weilin Biological Pharmaceutical Co., Ltd., received a single plasma collection license from the Inner Mongolia Health Commission, allowing it to operate two plasma collection stations[19] - The company’s subsidiary, Bohui Biological Pharmaceutical Co., Ltd., received approval for clinical trials of a trivalent influenza virus subunit vaccine from the National Medical Products Administration[19] - The company signed a guarantee contract with Bank of Communications, agreeing to provide a maximum guarantee of ¥10,300,000 for its subsidiary[20] - The company applied for a loan of ¥500,000,000 from Industrial and Commercial Bank of China, with a term of 7 years, backed by various collateral including equity and property[21] Inventory and Receivables - Accounts receivable increased to ¥71,865,977.47 from ¥58,575,220.53, indicating a rise of about 22.6%[24] - Inventory levels stood at ¥1,026,038,590.79, slightly up from ¥1,011,258,014.00, reflecting a growth of approximately 1.5%[24] - The company’s total current assets amounted to ¥1,471,574,373.76, compared to ¥1,226,324,965.41 at the start of the period, marking an increase of around 20%[24] Financial Expenses - The company experienced a 31.94% increase in financial expenses, amounting to ¥8,271,572.14, attributed to higher interest expenses and bank guarantee fees[12] - Research and development expenses were ¥13,846,347.86, slightly down from ¥14,556,648.09, reflecting a decrease of about 5%[30]